Elevated cyclic AMP and PDE4 inhibition induce chemokine expression in human monocyte-derived macrophages |
| |
| Authors: | Angie L Hertz Andrew T Bender Kimberly C Smith Mark Gilchrist Paul S Amieux Alan Aderem Joseph A Beavo |
| |
| Institution: | aDepartment of Pharmacology, University of Washington Medical School, Seattle, WA 98195; and ;bInstitute for Systems Biology, Seattle, WA 98103 |
| |
| Abstract: | Macrophages are central mediators of the innate immune system that can be differentiated from monocytes upon exposure to cytokines. While increased cyclic adenosine monophosphate (cAMP) levels are known to inhibit many lipopolysaccharide-elicited macrophage inflammatory responses, the effects of elevated cAMP on monocyte/macrophage differentiation are not as well understood. We show here that during differentiation, cAMP agonists can cause a large increase in the mRNA and protein levels of several of the pro-inflammatory CXCL and CCL chemokines. The cAMP mediator-exchange protein activated by cAMP (Epac) contributes substantially to the increase in these chemokines. These chemokines are known to play an important role in the regulation of immune responses, particularly regarding the pathogenesis of asthma and chronic obstructive pulmonary disorder. We also found that a selective cAMP-degrading phosphodiesterase (PDE) 4 inhibitor can potentiate the chemokine expression elicited by low-dose forskolin or Prostaglandin E2 (PGE2). These data suggest that chemokine receptor antagonists administered in conjunction with a PDE4 inhibitor may improve both the efficacy and safety of PDE4-inhibitor therapy for chronic inflammatory disorders. |
| |
| Keywords: | inflammation phosphodiesterase |
|
|
